NTLA-2001: opening a new era for gene therapy

Tongtong Cui; Bojin Li; Wei Li

doi:10.1093/lifemedi/lnac036

PDF(179 KB)

Life Medicine ›› 2022, Vol. 1 ›› Issue (2) : 49-51. DOI: 10.1093/lifemedi/lnac036

News & Opinion

NTLA-2001: opening a new era for gene therapy

Tongtong Cui¹^,²^,³ ,
Bojin Li¹^,²^,⁴ ,
Wei Li¹^,²^,³^,⁴

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Tongtong Cui, Bojin Li, Wei Li. NTLA-2001: opening a new era for gene therapy. Life Medicine, 2022, 1(2): 49‒51 https://doi.org/10.1093/lifemedi/lnac036

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	GillmoreJD, GaneE, TaubelJ, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021;385:493–502. CrossRef Google scholar

[2]	AimoA, Castiglione V, RapezziC, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol 2022;19:655–67. CrossRef Google scholar

[3]	AdliM. The CRISPR tool kit for genome editing and beyond. Nat Commun 2018;9:1–13. CrossRef Google scholar

[4]	FinnJD, SmithAR, PatelMC, et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 2018;22:2227–35. CrossRef Google scholar

[5]	WoodK, PinkM, SeitzerJ, et al. Development of NTLA-2001, a CRISPR/Cas9 genome editing therapeutic for the treatment of ATTR. Presented at the Second European Congress for ATTR Amyloidosis, Berlin, September 1–3, 2019.